Investing
Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal
© Reuters. FILE PHOTO: Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) – Bristol-Myers Squibb (NYSE:) is set to acquire cancer drugmaker Mirati Therapeutics (NASDAQ:) for $58 per share in cash, representing $4.8 billion equity value.
Bristol-Myers Squibb will finance the transaction with a combination of cash and debt.
The transaction is expected to be dilutive to Bristol-Myers Squibb’s non-GAAP earnings per share by approximately 35 cents per share in the first 12 months after the transaction closes.
Read the full article here
-
Personal Finance7 days ago
If you are 60 years old, new 401(k) rules could save you money
-
Investing6 days ago
Bank regulator gives BlackRock new deadline on bank stakes, Bloomberg reports By Reuters
-
Side Hustles5 days ago
LA Rental Prices Skyrocketing Despite Price Gouging Laws
-
Side Hustles5 days ago
How to Craft Marketing Campaigns That Reach Multiple Generations
-
Side Hustles7 days ago
FileJump Offers 2TB of Cloud Storage for $70—With No Strings Attached
-
Side Hustles3 days ago
What to Do If TikTok is Banned — How to Protect Your Brand
-
Side Hustles6 days ago
Zillow: These Are the Top 10 Hottest Housing Markets of 2025
-
Investing7 days ago
It’s Time to Rewrite Your Company’s Values — Here’s How